dexmedetomidine + ethanol + lidocaine

Dexmedetomidine + ethanol + lidocaine is a combination drug therapy evaluated for use in splanchnic nerve neurolysis (SNN) to manage chronic, debilitating intra-abdominal cancer pain, particularly from pancreatic and other upper abdominal malignancies. In this combination, **ethanol** (96%) serves as the primary neurolytic agent, inducing permanent nerve destruction through dehydration and protein precipitation of the splanchnic nerves. **Lidocaine** is a local anesthetic included to provide immediate, short-term analgesia and to help confirm the correct placement of the needle before the neurolytic agent is administered. **Dexmedetomidine** is a highly selective alpha-2 adrenergic receptor agonist added as an adjuvant; it enhances the quality and duration of the block by providing dose-dependent analgesia, sympatholysis, and anxiolysis without causing significant respiratory depression. This specific protocol was developed and studied by researchers at **Minia University** to improve the efficacy of chemical neurolysis in palliative care.

Other names

Dexmedetomidine-adjuvanted splanchnic nerve neurolysis solutionDexmedetomidine + Alcohol + Lidocaine